Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Mauro Alaibac
Based on 19 articles published since 2010
(Why 19 articles?)
||||

Between 2010 and 2020, M. Alaibac wrote the following 19 articles about Melanoma.
 
+ Citations + Abstracts
1 Review Electrochemotherapy of superficial tumors - Current status:: Basic principles, operating procedures, shared indications, and emerging applications. 2019

Campana, Luca G / Miklavčič, Damijan / Bertino, Giulia / Marconato, Roberto / Valpione, Sara / Imarisio, Ilaria / Dieci, Maria Vittoria / Granziera, Elisa / Cemazar, Maja / Alaibac, Mauro / Sersa, Gregor. ·Department of Surgery Oncology and Gastroenterology (DISCOG), University of Padua, Italy; Surgical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address: luca.giovanni.campana@gmail.com. · University of Ljubljana, Faculty of Electrical Engineering, Ljubljana, Slovenia. · Department of Otolaryngology Head Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. · University of Padua School of Surgery, Padua, Italy. · Christie NHS Foundation Trust, Manchester, UK. · Medical Oncology Unit, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. · Surgical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; Medical Oncology-2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. · Anesthesiology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. · Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. · Dermatology, Department of Medicine, University of Padua, Padua, Italy. ·Semin Oncol · Pubmed #31122761.

ABSTRACT: Treatment of superficial tumors with electrochemotherapy (ECT) has shown a steep rise over the past decade and indications range from skin cancers to locally advanced or metastatic neoplasms. Based on reversible electroporation, which is a physical method to achieve transient tumor cell membrane permeabilization by means of short electric pulses, ECT increases cellular uptake of bleomycin and cisplatin and their cytotoxicity by 8,000- and 80-fold, respectively. Standard operating procedures were established in 2006 and updated in 2018. Ease of administration, patient tolerability, efficacy across histotypes, and repeatability are peculiar advantages, which make standard ECT (ie, ECT using fixed-geometry electrodes) a reliable option for controlling superficial tumor growth locally and preventing their morbidity. Consolidated indications include superficial metastatic melanoma, breast cancer, head and neck skin tumors, nonmelanoma skin cancers, and Kaposi sarcoma. In well-selected patients with oropharyngeal cancers, ECT ensures appreciable symptom control. Emerging applications include skin metastases from visceral or hematological malignancies, vulvar cancer, and some noncancerous skin lesions (keloids and capillary vascular malformations). Repeatability and integration with other oncologic therapies allow for consolidation of response and sustained tumor control. In this review, we present the basic principles of ECT, recently updated operating procedures, anesthesiological management, and provide a synthesis of the efficacy of standard ECT across histotypes.

2 Review Recent advances in localized immunotherapy of skin cancers. 2019

Russo, Irene / Sernicola, Alvise / Alaibac, Mauro. ·Unit of Dermatology, University of Padua, Via Gallucci 4, Padova 35128, Italy. ·Immunotherapy · Pubmed #30786845.

ABSTRACT: Skin cancer is the most frequent malignancy in humans. The immune system has long been known to have an important role in defeating cancer. Immunotherapy, which includes various strategies to enhance tumor immunity, currently represents an exciting option for the treatment of skin cancers. Local immunotherapy is a promising therapeutic approach and may improve response rates without inducing systemic toxicity. Here, we review the main localized immunotherapies for the management of skin cancer with a special focus on advanced melanoma, nonmelanoma skin cancer and primary cutaneous lymphoma.

3 Review Vitamins and Melanoma. 2015

Russo, Irene / Caroppo, Francesca / Alaibac, Mauro. ·Unit of Dermatology, University of Padua, Via Battisti 206, 35128 Padua, Italy. irenerusso88@yahoo.it. · Unit of Dermatology, University of Padua, Via Battisti 206, 35128 Padua, Italy. francesca.caroppo@studenti.unipd.it. · Unit of Dermatology, University of Padua, Via Battisti 206, 35128 Padua, Italy. mauro.alaibac@unipd.it. ·Cancers (Basel) · Pubmed #26213971.

ABSTRACT: A tremendous amount of information was published over the past decades in relation to the role of vitamins in various neoplastic diseases. In particular, several studies showed an inverse relationship between selected vitamins intake and cancer risk. In this review we will focus on the role played by vitamins in melanoma with particular regard to vitamin A, D, K, E and C. Given that vitamin supplementation is easy, convenient, and readily accepted by patients, in the future the use of vitamins in chemoprevention and therapy of melanoma could be encouraged if supported by pre-clinical and clinical evidence.

4 Review Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. 2014

Rastrelli, Marco / Tropea, Saveria / Rossi, Carlo Riccardo / Alaibac, Mauro. ·Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy marco.rastrelli@ioveneto.it. · Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy. · Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS and Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. · Dermatology Unit, University of Padova, Padova, Italy. ·In Vivo · Pubmed #25398793.

ABSTRACT: This article reviews epidemiology, risk factors, pathogenesis and diagnosis of melanoma. Data on melanoma from the majority of countries show a rapid increase of the incidence of this cancer, with a slowing of the rate of incidence in the period 1990-2000. Males are approximately 1.5-times more likely to develop melanoma than females, while according to other studies, the different prevalence in both sexes must be analyzed in relation with age: the incidence rate of melanoma is grater in women than men until they reach the age of 40 years, however, by 75 years of age, the incidence is almost 3-times as high in men versus women. The most important and potentially modifiable environmental risk factor for developing malignant melanoma is the exposure to ultraviolet (UV) rays because of their genotoxic effect. Artificial UV exposure may play a role in the development of melanoma. The most important host risk factors are the number of melanocytic nevi, familiar history and genetic susceptibility. A patient with a personal history of melanoma must be considered at greater risk for subsequent melanoma. Indeed approximately 1-8% of patients with prior history of melanoma will develop multiple primary melanomas. We herein review the dermatological diagnosis and classification of melanoma.

5 Review Cutaneous melanoma in solid organ transplant patients. 2014

Russo, I / Piaserico, S / Belloni-Fortina, A / Alaibac, M. ·Dermatology Unit, Department of Medicine University of Padua, Padua, Italy - mauro.alaibac@unipd.it. ·G Ital Dermatol Venereol · Pubmed #25068225.

ABSTRACT: Solid organ transplant patients are at greatly increased risk of developing a wide variety of skin cancers, particularly epithelial skin cancers. On the other hand, it is well known that an intact immune system limits the development of benign melanocytic lesions. The eruptive nevi phenomenon, which we can observe in solid organ transplant recipients, is indicative of the relationship between melanocyte proliferation and immune system. Regression of melanocytic nevi after restoration of complete immune responsiveness is a further clinical example the role of immunosurveillance on melanocyte proliferation. However, melanoma incidence in organ transplant recipients appears only 2-3 folds higher than in general population. To this regard, organ transplant recipients who develop de novo melanomas thicker than 2mm seem to have a significantly worse outcome with a greatly increased risk of dying of metastatic melanoma, whereas those who develop a ≤2 mm thickness melanoma seem to have a prognosis similar to that of the general population. Furthermore, there is no evidence supporting an increased risk of melanoma recurrences after transplant in patients with a history of low-risk melanoma. Melanoma is also one of the most frequent and lethal donor-derived malignancies suggesting that a history of invasive melanoma should be considered an absolute contraindication to donation. The aim of this review is to investigate the relationship between immunosuppression and melanoma and to discuss its clinical implications for the management of transplant-associated melanoma.

6 Review Melanoma m1: diagnosis and therapy. 2014

Rastrelli, Marco / Tropea, Saveria / Pigozzo, Jacopo / Bezzon, Elisabetta / Campana, Luca Giovanni / Stramare, Roberto / Alaibac, Mauro / Rossi, Carlo Riccardo. ·Melanoma and Sarcoma Unit, Veneto Institute of Oncology IOV-IRCCS Padova, Italy. marco.rastrelli@ioveneto.it. ·In Vivo · Pubmed #24815827.

ABSTRACT: This article reviews the epidemiology, pathogenesis, diagnosis, prognostic factors and treatment of metastatic melanoma, including the most recent developments in the specific field. It examines the sequential and non-linear models of development and progression of melanoma and the main molecular disorder involved in these processes. Clinical and diagnostic aspects have been divided according to clinical staging. Surgical resectability, the site and number of metastases, the number of involved organs, the duration of remission, serum lactate dehydrogenase levels and tumor doubling-time have the greatest prognostic value. Surgical treatment has been analyzed considering its rational function and examining all sites involved in metastasis. We also discuss the palliative role of radiotherapy in relation to various metastatic sites, chemotherapy and recently introduced targeted-therapy. The association of newer drugs and new biological therapies such as ipilimumab and verumafenib have improved the treatment landscape of stage IV melanoma.

7 Review Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α. 2012

Zonta, Elisa / Chiarion, Vanna / Zarian, Haik / Peserico, Andrea / Alaibac, Mauro. · ·Melanoma Res · Pubmed #22543678.

ABSTRACT: -- No abstract --

8 Article A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. 2020

Rastrelli, Marco / Del Fiore, Paolo / Buja, Alessandra / Vecchiato, Antonella / Rossi, Carlo Riccardo / Chiarion Sileni, Vanna / Tropea, Saveria / Russano, Francesco / Zorzi, Manuel / Spina, Romina / Cappellesso, Rocco / Mazzarotto, Renzo / Cavallin, Francesco / Bassetto, Franco / Bezzon, Elisabetta / Ferrazzi, Beatrice / Alaibac, Mauro / Mocellin, Simone. ·Surgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. · Department of Cardiological, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. · Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy. · Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. · Veneto Tumour Registry, Azienda Zero, Padua, Italy. · Surgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy. · Department of Surgery and Oncology, Unit of Radiotherapy, Hospital Trust of Verona, Verona, Italy. · Independent Statistician, Solagna, Italy. · Clinic of Plastic Surgery, Department of Neuroscience, Padua University Hospital, University of Padua, Padua, Italy. · Radiology Unit, Department of Imaging and Medical Physics, Istituto Oncologico Veneto IOV IRCSS, Padua, Italy. · Postgraduate School of Occupational Medicine, University of Verona, Verona, Italy. · Unit of Dermatology, University of Padua, Padua, Italy. ·Front Oncol · Pubmed #32351898.

ABSTRACT: Merkel Cell Carcinoma (MCC) is a highly aggressive neuroendocrine neoplasm of the skin. Due to its rarity, the management of MCC is not standardized across centers. In this article, we present the experience of the Veneto region in the North-East of Italy, where a committee of skin cancer experts has proposed a clinical pathway for the diagnosis and treatment of MCC. Putting together the evidence available in the international literature, we outlined the best approach to the management of patients affected with this malignancy step- by- step for each possible clinical situation. Crucial in this pathway is the role of the multidisciplinary team to deal with the lack of robust information on each aspect of the management of this disease.

9 Article Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. 2017

Pizzichetta, Maria A / Massi, Daniela / Mandalà, Mario / Queirolo, Paola / Stanganelli, Ignazio / De Giorgi, Vincenzo / Ghigliotti, Giovanni / Cavicchini, Stefano / Quaglino, Pietro / Corradin, Maria T / Rubegni, Pietro / Alaibac, Mauro / Astorino, Stefano / Ayala, Fabrizio / Magi, Serena / Mazzoni, Laura / Manganoni, Maria Ausilia / Talamini, Renato / Serraino, Diego / Palmieri, Giuseppe / Anonymous1830926. ·Division of Oncology B, CRO Aviano National Cancer Institute, Via Franco Gallini 2, 33081, Aviano, Italy. pizzichetta@cro.it. · Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy. · Unit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy. · Department of Medical Oncology, National Institute for Cancer Research, IRCCS San Martino, Genoa, Italy. · Skin Cancer Unit, Istituto Tumori Romagna (IRST), Meldola, Italy. · Department of Dermatology, University of Parma, Parma, Italy. · Department of Dermatology, University of Florence, Florence, Italy. · Clinic of Dermatology, IRCCS San Martino-IST, Genoa, Italy. · Department of Dermatology, Fondazione Ospedale Maggiore Policlinico IRCCS, Milan, Italy. · Dermatologic Clinic, Dept Medical Sciences, University of Torino, Turin, Italy. · Division of Dermatology, Pordenone Hospital, Pordenone, Italy. · Department of Dermatology, University of Siena, Siena, Italy. · Department of Dermatology, University of Padova, Padua, Italy. · Division of Dermatology, Celio Hospital, Rome, Italy. · National Cancer Institute, "Fondazione G. Pascale"-IRCCS, Naples, Italy. · Department of Dermatology, ASST degli Spedali Civili di Brescia, Brescia, Italy. · Unit of Epidemiology and Biostatistics, CRO Aviano National Cancer Institute, Aviano, Italy. · Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy. ·J Transl Med · Pubmed #29115977.

ABSTRACT: BACKGROUND: Nodular melanoma (NM) accounts for most thick melanomas and because of their frequent association with ulceration, fast growth rate and high mitotic rate, contribute substantially to melanoma-related mortality. In a multicentric series of 214 primary melanomas including 96 NM and 118 superficial spreading melanoma (SSM), histopathological features were examined with the aim to identify clinicopathological predictors of recurrence. METHODS: All consecutive cases of histopathologically diagnosed primary invasive SSM and NM during the period 2005-2010, were retrieved from the 12 participating Italian Melanoma Intergroup (IMI) centers. Each center provided clinico-pathological data such as gender, age at diagnosis, anatomical site, histopathological conventional parameters, date of excision and first melanoma recurrence. RESULTS: Results showed that NM subtype was significantly associated with Breslow thickness (BT) at multivariate analysis: [BT 1.01-2 mm (OR 7.22; 95% CI 2.73-19.05), BT 2.01-4 mm (OR 7.04; 95% CI 2.54-19.56), and BT > 4 mm (OR 51.78; 95% CI 5.65-474.86) (p < 0.0001)]. Furthermore, mitotic rate (MR) was significantly correlated with NM histotype: [(MR 3-5 mitoses/mm CONCLUSIONS: We found that NM subtype was significantly associated with higher BT and MR but it was not a prognostic factor since it did not significantly correlate with melanoma recurrence rate. Conversely, increased BT and MR as well as SNLB positivity were significantly associated with a higher risk of melanoma recurrence.

10 Article A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. 2017

Russo, Irene / Zorzetto, Ludovica / Frigo, Anna Chiara / Chiarion Sileni, Vanna / Alaibac, Mauro. ·Unit of Dermatology, University of Padua, Via Gallucci 4, 35128 Padova, Italy. · Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences University of Padua Via Loredan, 18, 35131 Padova, Italy. · Unit of Medical Oncology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy. ·Eur J Dermatol · Pubmed #29084636.

ABSTRACT: Patients with advanced melanoma have a poor prognosis. Since the discovery of BRAF mutations in cutaneous melanoma, new pharmacological agents have been developed to inhibit this target. Although the survival of patients with advanced melanoma has improved with BRAF inhibitors, the emergence of drug resistance and the high incidence of cutaneous side effects represent important limitations. The aim of our study was to compare the incidence of cutaneous side effects between BRAF inhibitor monotherapy and BRAF and MEK inhibitor combination therapy in our cohort of patients. This study was a longitudinal prospective observational study. The study population comprised 83 patients with advanced cutaneous melanoma presenting with BRAF V600 mutation. The inclusion criteria included: age above 18 years, metastatic cutaneous melanoma or melanoma with high risk of metastasis, the presence of BRAF V600 mutation, and treatment with BRAF inhibitors or a combination of BRAF and MEK inhibitors. The majority of patients developed skin toxicity during treatment. The most common cutaneous side effects were localized hyperkeratosis and verrucous keratosis. Other cutaneous side effects observed were photosensitivity, squamous cell carcinoma, and keratoacanthoma. Our results indicate that cutaneous side effects are generally observed during BRAF inhibitor monotherapy and are significantly different from those observed in patients treated with combination therapy.

11 Article Toll-like receptors and cutaneous melanoma. 2016

Coati, Ilaria / Miotto, Serena / Zanetti, Irene / Alaibac, Mauro. ·Department of Medicine, Unit of Dermatology, University of Padua, Padua 35128, Italy. ·Oncol Lett · Pubmed #27900049.

ABSTRACT: Innate immune cells recognize highly conserved pathogen-associated molecular patterns (PAMPs) via pattern recognition receptors (PRRs). Previous studies have demonstrated that PRRs also recognize endogenous molecules, termed damage-associated molecular patterns (DAMPs) that are derived from damaged cells. PRRs include Toll-like receptors (TLRs), scavenger receptors, C-type lectin receptors and nucleotide oligomerization domain-like receptors. To date, 10 TLRs have been identified in humans and each receptor responds to a different ligand. The recognition of PAMPS or DAMPs by TLRs leads to the activation of signaling pathways and cellular responses with subsequent pro-inflammatory cytokine release, phagocytosis and antigen presentation. In the human skin, TLRs are expressed by keratinocytes and melanocytes: The main cells from which skin cancers arise. TLRs 1-6 and 9 are expressed in keratinocytes, while TLRs 2-5, 7, 9 and 10 have been identified in melanocytes. It is hypothesized that TLRs may present a target for melanoma therapies. In this review, the involvement of TLRs in the pathogenesis and treatment of melanoma was discussed.

12 Article TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma. 2016

Elefanti, Lisa / Sacco, Giorgia / Stagni, Camilla / Rastrelli, Marco / Menin, Chiara / Russo, Irene / Alaibac, Mauro. ·Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, Scientific Institute for Hospitalization, Treatment and Research, Padua I-35128, Italy. · Department of Medicine, Dermatology Unit, University of Padua, Padua I-35121, Italy. · Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Unit, University of Padua, Padua I-35100, Italy. · Melanoma and Soft Tissue Sarcoma Unit, Veneto Institute of Oncology, Scientific Institute for Hospitalization, Treatment and Research, Padua I-35128, Italy. ·Oncol Lett · Pubmed #27347137.

ABSTRACT: Cutaneous melanoma is a life-threatening skin cancer. Its incidence is rapidly increasing, and early diagnosis is the main factor able to improve its poor prognosis. Toll-like receptors (TLRs) are transmembrane glycoproteins that recognize pathogen- and damage-associated molecular patterns, against which TLRs activate the innate immune response and initiate the adaptive immune response. Genetic variations of these receptors may alter the immune system, and are involved in evolution and susceptibility to various diseases, including cancer. The aim of the present study was to evaluate whether the presence of TLR7 glutamine (Gln) 11 leucine (Leu) polymorphism confers an increased susceptibility to cutaneous melanoma. For that purpose, a case-control study was performed with 182 melanoma cases and 89 controls. To highlight the possible association between the aforementioned polymorphism and the susceptibility to melanoma, 93 cases of single melanoma and 89 cases of multiple primary melanoma (MPM) were compared in the present study. Since the TLR7 gene is localized on the chromosome X, the allelic frequency of the Gln11Leu polymorphism was analyzed separately in males and females. The distribution of allele frequencies between melanoma cases and controls (P=0.245) and between single melanoma and MPM cases (P=0.482) was not significant. Therefore, the present results do not suggest an association between TLR7 Gln11Leu polymorphism and susceptibility to cutaneous melanoma. Further studies are required to analyze the influence of other TLR polymorphisms on the susceptibility to malignant melanoma and the involvement of innate immunity in this malignancy.

13 Article Long-term Survival of Patients With Invasive Ultra-thin Cutaneous Melanoma: A Single-center Retrospective Analysis. 2016

Vecchiato, Antonella / Zonta, Elisa / Campana, Luca / Dal Bello, Giacomo / Rastrelli, Marco / Rossi, Carlo Riccardo / Alaibac, Mauro. ·From the Melanoma and Soft Tissue Sarcoma Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy (AV, LC, MR, CRR) · and Dermatology Unit, University of Padua, Padua, Italy (EZ, GDB, MA). ·Medicine (Baltimore) · Pubmed #26765437.

ABSTRACT: The incidence of cutaneous melanoma is increasing worldwide, especially for thin melanoma (Breslow ≤1 mm). Thin cutaneous melanoma has a favorable prognosis but there are few data about the prognosis of patients with ultra-thin cutaneous melanoma (Breslow ≤ 0.5 mm). Our aim was to investigate the disease-free survival among patients with invasive cutaneous melanoma with Breslow ≤ 0.5 mm after 10 years from the initial diagnosis.A retrospective review of 240 cutaneous melanoma patients with Breslow ≤ 0.5 mm was performed. Recurrence, death from cutaneous melanoma, and disease-free survival were all identified.In the whole group of patients, we observed only 2 deaths from cutaneous melanoma. Median follow-up was 13, 11 years. Among all 240 patients, 221 were alive and disease free, 2 died of cutaneous melanoma, 11 died of other non-neoplastic diseases, 5 died of other neoplastic diseases different from melanoma, and 1 patient had a local recurrence; therefore the 10-year melanoma survival rate was 99.6%.Our data indicate that death from cutaneous melanoma in the group of patients with Breslow ≤0.5 mm was a very rare event and that diagnosis at this stage dramatically decreases the risk of developing metastatic tumors to a <0.5% also after a 10-year period of follow-up. Limitation of the study includes the fact that other risk factors for melanoma, notably ulceration, and mitotic rate, were not evaluated.

14 Article Differences in clinicopathological features and distribution of risk factors in Italian melanoma patients. 2015

Fava, P / Astrua, C / Chiarugi, A / Crocetti, E / Pimpinelli, N / Fargnoli, M C / Maurichi, A / Rubegni, P / Manganoni, A M / Bottoni, U / Catricalà, C / Cavicchini, S / Santinami, M / Alaibac, M / Annetta, A / Borghi, A / Calzavara Pinton, P / Capizzi, R / Clerico, R / Colombo, E / Corradin, M T / De Simone, P / Fantini, F / Ferreli, C / Filosa, G / Girgenti, V / Giulioni, E / Guarneri, C / Lamberti, A / Lisi, P / Nardini, P / Papini, M / Peris, K / Pizzichetta, M A / Salvini, C / Savoia, P / Strippoli, D / Tolomio, E / Tomassini, M A / Vena, G A / Zichichi, L / Patrizi, A / Argenziano, G / Simonacci, M / Quaglino, P. ·Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy. ·Dermatology · Pubmed #25659983.

ABSTRACT: BACKGROUND: No studies are available in the literature on the distribution of different melanoma features and risk factors in the Italian geographical areas. OBJECTIVE: To identify the differences in clinical-pathological features of melanoma, the distribution of risk factors and sun exposure in various Italian macro-areas. METHODS: Multicentric-observational study involving 1,472 melanoma cases (713 north, 345 centre, 414 south) from 26 referral centres belonging to the Italian Multidisciplinary Group for Melanoma. RESULTS: Melanoma patients in northern regions are younger, with thinner melanoma, multiple primaries, lower-intermediate phototype and higher counts of naevi with respect to southern patients; detection of a primary was mostly connected with a physician examination, while relatives were more involved in the south. Northern patients reported a more frequent use of sunbeds and occurrence of sunburns before melanoma despite sunscreen use and a lower sun exposure during the central hours of the day. CONCLUSIONS: The understanding of differences in risk factors distribution could represent the basis for tailored prevention programmes.

15 Article Histopathological characteristics of subsequent melanomas in patients with multiple primary melanomas. 2014

Vecchiato, A / Pasquali, S / Menin, C / Montesco, M C / Alaibac, M / Mocellin, S / Campana, L G / Nitti, D / Rossi, C R. ·Melanoma and Sarcomas Unit, Veneto Institute of Oncology, Padova, ItalyDepartment of Oncological and Surgical Sciences, University of Padova, Padova, ItalyImmunology and Molecular Oncology Unit, Veneto Institute of Oncology, Padova, ItalyPathology Unit, Veneto Institute of Oncology, Padova, ItalyDermatology Unit, University of Padova, Padova. ·J Eur Acad Dermatol Venereol · Pubmed #23216522.

ABSTRACT: BACKGROUND: Multiple primary melanomas (MPM) occur in up to 20% of melanoma patients, and subsequent tumours seem to have a favourable histopathological pattern. OBJECTIVE: A prospectively collected cohort of 194 patients with MPM was retrospectively reviewed to investigate clinical and histopathological features of first and subsequent melanomas. METHODS: Patients with MPM who were diagnosed at our Department (1985-2011) and who attended at least a follow-up control yearly were identified. RESULTS: The number of nevi was <10, 10-50 and >50 in 8.7%, 41% and 50.3% of patients respectively. Histopathological dysplastic nevi have been diagnosed in 105 patients. During a median follow-up of 58 months, 159 (81.9%), 24 (12.3%), 7 (3.6%) and 4 (2%) patients developed 2, 3, 4 and ≥ 5 melanomas, respectively. The median time to second primary melanoma was 45 months. The second primary melanoma was diagnosed within 1-year and after 5-year from the first melanoma in 36.6% and 17.3% of patients respectively. First and second primary melanomas were in situ in 41 (21%) and 104 (54%) patients respectively (P < 0.001). Among patients with ≥ 2 invasive melanomas (N = 80), median tumour thickness and ulceration of first and second primaries were 0.91 and 0.44 mm (P <0.001), and 32% and 7.7% (P = 0.001) respectively. CONCLUSIONS: Subsequent melanomas occurred within 1-year from the appearance of the first melanoma in 36% of patients with MPM, while a late melanoma diagnosis was detected in 17% of cases. Second primary melanoma had favourable histopathological features. Our findings support long-term skin surveillance to detect subsequent melanomas at an early stage.

16 Article Achromic superficial spreading melanoma accidentally treated with imiquimod. 2012

Zattra, Edoardo / Salmaso, Roberto / Tonin, Elena / Alaibac, Mauro. ·Dermatology Unit, University of Padua, Padova, Italy. ·Acta Derm Venereol · Pubmed #21725584.

ABSTRACT: -- No abstract --

17 Article Nevus spilus and melanoma: case report and review of the literature. 2010

Corradin, Maria Teresa / Zattra, Edoardo / Fiorentino, Renzo / Alaibac, Mauro / Belloni-Fortina, Anna. ·Unit of Dermatology, Azienda Ospedaliera Santa Maria degli Angeli di Pordenone, Padua, Italy. ·J Cutan Med Surg · Pubmed #20338124.

ABSTRACT: BACKGROUND: Nevus spilus is characterized by a pigmented patch with scattered flat or maculopapular speckles. Nevus spilus was first described by Burkley in 1842. Since then, this lesion has been widely debated in the literature, particularly for the possible occurrence of melanoma within the lesion. OBJECTIVE: We describe the case of a 65-year-old female presenting with a nodular achromic melanoma that occurred within a nevus spilus on the left thigh. CONCLUSION: Our observation is consistent with the idea that this entity in some circumstances may have the ability to evolve into a malignant melanoma.

18 Minor Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma. 2017

Pizzichetta, M A / Kittler, H / Stanganelli, I / Ghigliotti, G / Corradin, M T / Rubegni, P / Cavicchini, S / De Giorgi, V / Bono, R / Alaibac, M / Astorino, S / Ayala, F / Quaglino, P / Pellacani, G / Argenziano, G / Guardoli, D / Specchio, F / Serraino, D / Talamini, R / Anonymous21310882. ·Division of Medical Oncology - Preventive Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy. · Department of Dermatology, Medical University of Vienna, Vienna, Austria. · Skin Cancer Unit, Istituto Tumori Romagna (IRST), Meldola, Department of Dermatology, University of Parma, Italy. · IRCCS San Martino - 1st Clinic of Dermatology, Genova, Italy. · Division of Dermatology, Pordenone Hospital, Pordenone, Italy. · Department of Dermatology, University of Siena, Siena, Italy. · Department of Dermatology, Fondazione Ospedale Maggiore Policlinico IRCCS, Milan, Italy. · Department of Dermatology, University of Florence, Florence, Italy. · Istituto Dermopatico Immacolata, IRCCS, Rome, Italy. · Department of Dermatology, University of Padova, Italy. · Division of Dermatology, Celio Hospital, Rome, Italy. · National Cancer Institute, 'Fondazione G. Pascale'-IRCCS, Naples, Italy. · Dermatologic Clinic, Department of Medical Sciences, University of Torino, Torino, Italy. · Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy. · Dermatology Unit, Second University of Naples, Naples, Italy. · Skin Cancer Unit, Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy. · Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy. ·Br J Dermatol · Pubmed #27681347.

ABSTRACT: -- No abstract --

19 Minor Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy. 2011

Menin, Chiara / Vecchiato, Antonella / Scaini, Maria Chiara / Elefanti, Lisa / Funari, Gloria / De Salvo, Gian Luca / Quaggio, Monica / Tognazzo, Silvia / Agata, Simona / Dalla Santa, Silvia / Montagna, Marco / Alaibac, Mauro / Chiarion-Sileni, Vanna / D'Andrea, Emma. · ·Pigment Cell Melanoma Res · Pubmed #21672182.

ABSTRACT: -- No abstract --